Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Al18F-PSMA-BCH PET/CT in PSMA-Positive Tumors
NCT05761366Phase 2Recruiting
- Sponsor
- Cancer Institute and Hospital, Chinese Academy of Medical Sciences
- Start
- Oct 2022
- Primary completion
- Oct 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of fibrostatin fluoride [18F] in prostate cancer (PCa), Transitional Cell Carcinoma (TCC), colon carcinoma, Adenoid cystic carcinoma (ACC), mesothelioma, sponsored by Cancer Institute and Hospital, Chinese Academy of Medical Sciences. Started Oct 2022; status: recruiting.
02
Drugs
fibrostatin fluoride [18F]
03
Conditions
prostate cancer (PCa)Transitional Cell Carcinoma (TCC)colon carcinomaAdenoid cystic carcinoma (ACC)mesothelioma
Beyond the preview
Go deeper on NCT05761366.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05761366.